Clinical trials: Non-small Cell Lung Cancer Stage IV
NSCLC Stage IV, NSCLC, Stage III
To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC
Primary Objectives: To evaluate the Quality of Life (QoL) score of adding oral Oligo Fucoidan to platinum-based chemotherapy in comparison with placebo in subjects with Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT03130829
- Testing
- Oligo Fucoidan
- Where
- 3 sites in Taiwan
- Sponsor
- Hi-Q Marine Biotech International, Ltd.
Non-small Cell Lung Cancer
Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy
The purpose of this study is to determine if Pemetrexed plus Carboplatin plus Bevacizumab plus Enzastaurin, followed by maintenance Bevacizumab plus Enzastaurin can extend survival time without disease progression in the…
- Trial name
- NCT00533429
- Testing
- enzastaurin, pemetrexed, carboplatin
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Study to determine the maximum tolerated dose (MTD) and safety profile of a single-dose administration of sibrotuzumab (50 mg) conjugated to an increasing dose of 131 I isotope.
- Trial name
- NCT02209727
- Testing
- 131I-Sibrotuzumab
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer Metastatic
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
Primary Objectives: Study was designed with multiple primary endpoints analyzed on randomized participants at the time of the cut-off date for each given analysis (progression free survival [PFS] and overall survival [OS]) Study…
- Trial name
- CARMEN-LC03 (NCT04154956)
- Testing
- SAR408701, Docetaxel
- Where
- 169 sites in United States, Argentina and 24 more
- Volunteers
- 389 people
- Sponsor
- Sanofi
Non Small Cell Lung Cancer
Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
This is an observational multicenter study. A cross-sectional descriptive study of patients with locally advanced or metastatic Non Small Cell Lung Cancer with activating EGFR mutation treated by any first line therapy will be…
- Trial name
- POSITHES (NCT05103605)
- Testing
- Osimertinib
- Where
- 46 sites in France
- Volunteers
- 274 people
- Sponsor
- AstraZeneca
Non-Squamous Non-Small Cell Lung Cancer
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone chemotherapy regimens in the first-line setting in…
- Trial name
- NCT01496742
- Testing
- RO5490258, bevacizumab [Avastin], cisplatin/carboplatin
- Where
- 87 sites in United States, Argentina and 11 more
- Volunteers
- 259 people
- Sponsor
- Genentech, Inc.
Carcinoma, Non-Small Cell Lung
ZD6474(Vandetanib) + Alimta Combo Study
The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets) to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help control their symptoms and disease better than…
- Conditions
- Carcinoma, Non-Small Cell Lung, Lung Cancer
- Trial name
- NCT00506051
- Testing
- ZD6474 (vandetanib) 100mg, pemetrexed, ZD6474 (vandetanib) 300mg
- Volunteers
- 21 people
- Sponsor
- Genzyme, a Sanofi Company
Non-small Cell Lung Cancer
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB264 in combination with KL-A167 with or without chemotherapy with advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT05351788
- Testing
- SKB264, KL-A167, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 110 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice
This prospective, observational study will assess the effectiveness and safety of Avastin (bevacizumab) as 1st line therapy in elderly patients with advanced non-squamous non-small cell lung cancer in clinical practice.
- Trial name
- NCT01893268
- Where
- 88 sites in France
- Volunteers
- 279 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
The primary objective of this study is to determine the overall response rate (complete response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel in patients with previously untreated locally…
- Trial name
- NCT00687817
- Testing
- bavituximab plus paclitaxel and carboplatin
- Where
- 9 sites in India
- Volunteers
- 49 people
- Sponsor
- Peregrine Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
This randomised, open label phase III trial will be performed in patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation.
- Trial name
- NCT00949650
- Testing
- Pemetrexed, BIBW 2992, Cisplatin
- Where
- 133 sites in United States, Argentina and 23 more
- Volunteers
- 345 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation…
- Trial name
- NCT05609968
- Testing
- Sacituzumab Govitecan, Pembrolizumab
- Where
- 180 sites in United States, Australia and 23 more
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small-cell Lung Cancer
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
This is a single-arm, open, multicenter phase II clinical study to evaluate the efficacy and safety of HL-085 capsules combined with Vemurafenib in the treatment of BRAF V600E mutated patients with unresectable locally advanced…
- Trial name
- NCT05900219
- Testing
- HL-085+Vemurafenib
- Volunteers
- 75 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Non-Squamous Non-Small Cell Lung Cancer
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
This single arm, open-label study will evaluate the efficacy and safety of erlotinib (Tarceva) in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)…
- Trial name
- NCT01260181
- Testing
- Erlotinib
- Where
- 9 sites in Portugal
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab
- Trial name
- CheckMate 955 (NCT03048136)
- Testing
- Nivolumab, Ipilimumab
- Where
- 17 sites in United States, Argentina and 3 more
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
This is a Phase II, randomized, open-label, active-controlled, multicenter study to compare intravenous uliledlimab combined with sintilimab and chemotherapy versus sintilimab combined with chemotherapy in patients with…
- Trial name
- NCT07005336
- Testing
- Uliledlimab, Sintilimab, Pemetrexed
- Where
- 28 sites in China
- Volunteers
- 150 people
- Sponsor
- TJ Biopharma Co., Ltd.
Non-small Cell Lung Caner, KRAS-mutated
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Aim to evaluate the efficacy and safety of luvometinib combined with anlotinib in patients with KRAS-mutated non-small cell lung caner
- Conditions
- Non-small Cell Lung Caner, KRAS-mutated, Metastasis, Previous Treamted
- Trial name
- NCT07562581
- Testing
- luvometinib + anlotinib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with relapsed stage IIIB or IV non small cell lung cancer.
- Trial name
- NCT00034164
- Testing
- S-8184 Paclitaxel Injectable Emulsion
- Where
- Russia
- Volunteers
- 52 people
- Sponsor
- Achieve Life Sciences
Lung Cancer - Non Small Cell Squamous
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.
- Trial name
- NCT01285609
- Testing
- Ipilimumab, Paclitaxel, Carboplatin
- Where
- 290 sites in United States, Argentina and 34 more
- Volunteers
- 1,289 people
- Sponsor
- Bristol-Myers Squibb
Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors.
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
- Trial name
- NCT07227298
- Testing
- PF-08634404, Sigvotatug Vedotin, PF-08046054/SGN-PDL1V
- Where
- 104 sites in United States, China and 7 more
- Volunteers
- 162 people
- Sponsor
- Pfizer